IGF-1 LR3 is a synthetic protein and lengthened analogue of human insulin-like growth factor 1 (IGF-1).It differs from native IGF-1 in that it possesses an arginine instead of a glutamic acid at the third position in its amino acid sequence ("arginine 3"), and also has an additional 13 amino acids at its N-terminus (MFPAMPLLSLFVN) ("long"), for a total of 83 amino acids (relative to the 70 of IGF-1).The consequences of these modifications are that IGF-1 LR3 retains the pharmacological activity of IGF-1 as an agonist of the IGF-1 receptor, has very low affinity for the insulin-like growth factor-binding proteins (IGFBPs), and has improved metabolic stability.

Usage

IGF-1 LR3 is primarily used to increase the biological activity of IGF. When IGF-1 LR3 is mobile in the body, it functions differently in individual types of tissues. For example, in muscle tissue, it forces the muscle to be more sensitive to insulin's effects, such as the decrease of fat storage.

IGF-1 LR3 is recommended to patients with the following conditions: hormone deficiency in children that results in short stature, adult growth deficiency, short bowel syndrome, short stature due to Turner Syndrome, adult deficiency associated with pituitary tumors or treatment of these tumors and muscle-wasting disease related to HIV/AIDS.

Mechanism of Action

IGF-1 LR3 binds to cell receptors in the muscle cells and activates cell communication, which then improves the growth rate of muscles.

IGF-1 LR3 obstructs the movement of glucose into the body’s cells. This facilitates fat burning and the use of fat in the body for the production of energy. IGF-1 LR3 has a life in the body for about 20-30 hours and therefore enhance the growth amount of muscle for a whole day.

Side Effects

Some possible side effects of IGF-1 LR3 may include the following: muscle and joint pain, nausea, headaches, hypoglycemia (usually when IGF-1 LR3 is administered in continuous high doses) and may be associated with increased risk of developing some cancers.